Article: Properties and therapeutic efficacy of broadly reactive chimeric and humanized H5-specific monoclonal antibodies against H5N1 influenza viruses

File Download Links for fulltext
(May Require Subscription)
Supplementary
  • Basic View
  • Metadata View
  • XML View
TitleProperties and therapeutic efficacy of broadly reactive chimeric and humanized H5-specific monoclonal antibodies against H5N1 influenza viruses
AuthorsZheng, Q1
Xia, L1
Wu, WL2
Zheng, Z1
Huo, Y1
Wu, J1
Liu, Y1
Yu, H1
Chen, Y1
Lau, SY2
Chen, H2
Luo, W1
Xia, N1
Issue Date2011
PublisherAmerican Society for Microbiology.
CitationAntimicrobial Agents And Chemotherapy, 2011, v. 55 n. 4, p. 1349-1357 [How to Cite?]
DOI: http://dx.doi.org/10.1128/AAC.01436-10
AbstractHighly pathogenic H5N1 virus infection causes severe disease and a high rate of fatality in humans. Development of humanized monoclonal antibodies may provide an efficient therapeutic regime for H5N1 virus infection. In the present study, broadly cross-reactive monoclonal antibodies (MAbs) derived from mice were humanized to minimize immunogenicity. One chimeric antibody (cAb) and seven humanized antibodies (hAbs) were constructed. These antibodies retained broad-spectrum reactivity to H5N1 viruses, binding to recombinant H5-subtype HA1 molecules expressed in CHO cells in a dose-dependent manner and exhibiting similar reactivities against antigenically distinct H5N1 viruses in hemagglutination inhibition (HI) assays. One humanized antibody, 37 hAb, showed HI and neutralization activities comparable to that of the parental murine antibody, 13D4 MAb, while the other six antibodies were less reactive to H5N1 viruses. Analysis of amino acid sequences in the variable region frameworks of the seven humanized antibodies found that Q5 and Y27 in the VH region are highly conserved murine residues. Comparison of the three-dimensional structures derived from the variable regions of MAbs 37 hAb, H1202-34, and 13D4 revealed that residue substitutions at sites 70 and 46 may be the major cause for the observed differences in binding affinity. Examination of the chimeric antibody and one of the humanized antibodies, 37 hAb, showed that both antibodies offered postinfection protection against lethal challenge with antigenically diverse H5N1 viruses in the mouse model. Chimeric and humanized antibodies which retain the broadly reactive and protective properties of murine H5-specific monoclonal antibodies have great potential for use in the treatment of human H5N1 infection. Copyright © 2011, American Society for Microbiology. All Rights Reserved.
ISSN0066-4804
2011 Impact Factor: 4.841
2011 SCImago Journal Rankings: 0.486
DOIhttp://dx.doi.org/10.1128/AAC.01436-10
ISI Accession Number IDWOS:000288594600004
Funding AgencyGrant Number
Science and Technology Foundation of Fujian Province2009YZ0002
National Natural Science Foundation of China30901077
Ministry of Health2008ZX10004-006
University Grants CommitteeAoE/M-12/06
National Institutes of HealthHHSN2662007 00005C
Research Fund for the Control of Infectious Diseases of the Health, Welfare, and Food Bureau of the Hong Kong SAR
Funding Information:

This study was supported by the Key Project of the Science and Technology Foundation of Fujian Province (grant no. 2009YZ0002), the National Natural Science Foundation of China (grant no. 30901077), the Key Project of the Ministry of Health (grant no. 2008ZX10004-006), the Areas of Excellence Scheme of the University Grants Committee (grant AoE/M-12/06), the National Institutes of Health (NIAID contract HHSN2662007 00005C), and the Research Fund for the Control of Infectious Diseases of the Health, Welfare, and Food Bureau of the Hong Kong SAR).

PubMed Central IDPMC3067186
ReferencesReferences in Scopus
GrantsControl of Pandemic and Inter-pandemic Influenza
DC Field
Value
dc.contributor.authorZheng, Q
dc.contributor.authorXia, L
dc.contributor.authorWu, WL
dc.contributor.authorZheng, Z
dc.contributor.authorHuo, Y
dc.contributor.authorWu, J
dc.contributor.authorLiu, Y
dc.contributor.authorYu, H
dc.contributor.authorChen, Y
dc.contributor.authorLau, SY
dc.contributor.authorChen, H
dc.contributor.authorLuo, W
dc.contributor.authorXia, N
dc.date.accessioned2011-10-28T02:45:35Z
dc.date.available2011-10-28T02:45:35Z
dc.date.issued2011
dc.description.abstractHighly pathogenic H5N1 virus infection causes severe disease and a high rate of fatality in humans. Development of humanized monoclonal antibodies may provide an efficient therapeutic regime for H5N1 virus infection. In the present study, broadly cross-reactive monoclonal antibodies (MAbs) derived from mice were humanized to minimize immunogenicity. One chimeric antibody (cAb) and seven humanized antibodies (hAbs) were constructed. These antibodies retained broad-spectrum reactivity to H5N1 viruses, binding to recombinant H5-subtype HA1 molecules expressed in CHO cells in a dose-dependent manner and exhibiting similar reactivities against antigenically distinct H5N1 viruses in hemagglutination inhibition (HI) assays. One humanized antibody, 37 hAb, showed HI and neutralization activities comparable to that of the parental murine antibody, 13D4 MAb, while the other six antibodies were less reactive to H5N1 viruses. Analysis of amino acid sequences in the variable region frameworks of the seven humanized antibodies found that Q5 and Y27 in the VH region are highly conserved murine residues. Comparison of the three-dimensional structures derived from the variable regions of MAbs 37 hAb, H1202-34, and 13D4 revealed that residue substitutions at sites 70 and 46 may be the major cause for the observed differences in binding affinity. Examination of the chimeric antibody and one of the humanized antibodies, 37 hAb, showed that both antibodies offered postinfection protection against lethal challenge with antigenically diverse H5N1 viruses in the mouse model. Chimeric and humanized antibodies which retain the broadly reactive and protective properties of murine H5-specific monoclonal antibodies have great potential for use in the treatment of human H5N1 infection. Copyright © 2011, American Society for Microbiology. All Rights Reserved.
dc.description.grantControl of Pandemic and Inter-pandemic Influenza
dc.description.grantcode97655
dc.description.naturelink_to_OA_fulltext
dc.identifier.citationAntimicrobial Agents And Chemotherapy, 2011, v. 55 n. 4, p. 1349-1357 [How to Cite?]
DOI: http://dx.doi.org/10.1128/AAC.01436-10
dc.identifier.doihttp://dx.doi.org/10.1128/AAC.01436-10
dc.identifier.epage1357
dc.identifier.hkuros197190
dc.identifier.isiWOS:000288594600004
Funding AgencyGrant Number
Science and Technology Foundation of Fujian Province2009YZ0002
National Natural Science Foundation of China30901077
Ministry of Health2008ZX10004-006
University Grants CommitteeAoE/M-12/06
National Institutes of HealthHHSN2662007 00005C
Research Fund for the Control of Infectious Diseases of the Health, Welfare, and Food Bureau of the Hong Kong SAR
Funding Information:

This study was supported by the Key Project of the Science and Technology Foundation of Fujian Province (grant no. 2009YZ0002), the National Natural Science Foundation of China (grant no. 30901077), the Key Project of the Ministry of Health (grant no. 2008ZX10004-006), the Areas of Excellence Scheme of the University Grants Committee (grant AoE/M-12/06), the National Institutes of Health (NIAID contract HHSN2662007 00005C), and the Research Fund for the Control of Infectious Diseases of the Health, Welfare, and Food Bureau of the Hong Kong SAR).

dc.identifier.issn0066-4804
2011 Impact Factor: 4.841
2011 SCImago Journal Rankings: 0.486
dc.identifier.issue4
dc.identifier.pmcidPMC3067186
dc.identifier.pmid21245446
dc.identifier.scopuseid_2-s2.0-79953208049
dc.identifier.spage1349
dc.identifier.urihttp://hdl.handle.net/10722/142417
dc.identifier.volume55
dc.languageeng
dc.publisherAmerican Society for Microbiology.
dc.publisher.placeUnited States
dc.relation.ispartofAntimicrobial Agents and Chemotherapy
dc.relation.referencesReferences in Scopus
dc.rightsAntimicrobial Agents and Chemotherapy. Copyright © American Society for Microbiology.
dc.rightsCopyright © American Society for Microbiology, Antimicrobial Agents and Chemotherapy, 2011, v. 55 n. 4, p. 1349-1357
dc.subject.meshAntibodies, Monoclonal - chemistry - immunology - therapeutic use
dc.subject.meshAntibodies, Viral - chemistry - immunology - therapeutic use
dc.subject.meshCHO Cells
dc.subject.meshCricetinae
dc.subject.meshInfluenza A Virus, H5N1 Subtype - immunology
dc.titleProperties and therapeutic efficacy of broadly reactive chimeric and humanized H5-specific monoclonal antibodies against H5N1 influenza viruses
dc.typeArticle
Author Affiliations
  1. Xiamen University
  2. The University of Hong Kong